Background: Numerous genetic variants have been confirmed as prostate cancer risk factors. These variants
Introduction
The TMPRSS2:ERG fusion is one of the most common molecular alterations in prostate cancer [1] . Forty to fifty percent of prostate tumors are fusion positive [2] , translating to more than 100,000 TMPRSS2:ERG positive prostate cancers diagnosed in the US annually [3] . The fusion involves the androgen-regulated promoter TMPRSS2 and the ETS transcription factor family member ERG. The discovery of TMPRSS2:ERG in 2005 was significant because it was the first common gene fusion identified in solid tumors, and it represents a model of hormonal regulation (by TMPRSS2) of an oncogene (ERG). TMPRSS2:ERG may thus define a distinct molecular subgroup of prostate cancers [4] . However, few studies have investigated whether tumors with and without the fusion have different etiologies, evidence that is key to prevention efforts.
Numerous genetic risk variants identified by genome-wide association studies (GWAS) have been confirmed as prostate cancer risk factors [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . A recent report brings the total number of risk SNPs to 100 [18] , a major step toward uncovering the genetic etiology of prostate cancer. It is known from family and twin studies that prostate cancer is highly heritable [19, 20] , and as risk SNPs are identified, they explain an ever-increasing portion (currently ~33%) of this underlying heritability in European Americans [18] .
Germline risk variants may confer susceptibility to the development of specific molecular alterations during tumor initiation and progression. Particularly as the development of TMPRSS2:ERG fusion is thought to be an early event in prostate carcinogenesis [21] , inherited risk variants may influence its occurrence. No study to date has investigated the association between known prostate cancer risk SNPs and the risk of molecular subtypes defined by presence or absence of the TMPRSS2:ERG fusion. We therefore tested this hypothesis within two prospective cohorts.
Materials and Methods

Study Participants
Physicians' Health Study (PHS) The men in this study are participants in two long-term, ongoing prospective: the PHS and HPFS. The PHS began in 1982 as a randomized, double-blind trial of aspirin and β-carotene in the prevention of cardiovascular disease and cancer among 22,071 healthy U.S. physicians aged 40-84 [22] . The HPFS, a prospective cohort study on the causes of cancer and heart disease in men, consists of 51,529 U.S. health professionals who were aged 40-75 years in 1986 [23] . In both studies, men were excluded if they had any serious medical conditions at baseline including all cancers (except non-melanoma skin cancer). Participants are followed through regular questionnaires to collect self-reported data on diet, lifestyle behaviors, medical history, and health outcomes, including prostate cancer.
Men diagnosed with prostate cancer and men never diagnosed with prostate cancer who were participants in these studies were included in the analyses. Cases were men diagnosed with incident, histologically confirmed 
Risk SNP Genotypes
Sixty-eight percent of PHS participants and 35% of HPFS participants provided a blood sample collected prior to cancer diagnosis. DNA was extracted from whole blood. 
ERG Status Measurement
In both cohorts, we sought to retrieve archival formalin-fixed paraffin embedded specimens. The PHS and HPFS Tumor Cohort includes men with prostate cancer from whom we have collected archival radical prostatectomy (RP) (95 percent) and trans-urethral resection of the prostate (TURP) (5 percent) specimens. 
Statistical Analysis
There were genotype data available for 487 men with prostate cancer and with ERG status (227 ERG+ and 260 ERG-cases), as well as 2600 controls. To examine the association of SNPs with ERG status, we performed unconditional logistic regression estimating odds ratios and 95% confidence intervals for each of the risk SNPs with the following outcomes: ERG+ vs ERG-cases, ERG+ cases vs controls, and ERG-cases vs controls. Risk SNPs were modeled as additive, with the homozygous genotype with the lowest risk (from original GWAS) as the referent. P-values from analyses comparing ERG+ with ERG-cases can be viewed as a p-value comparing the association of the SNP with the risk of ERG+ cancer to the association of the SNP with the risk of ERG-cancer. Analyses were performed with SAS version 9.3. All p-values reported are twosided and unadjusted for multiple comparisons (p<0.05 considered significant). Table 2 . When comparing the ERG+ to the ERG-cancers, an odds ratio (OR) greater than 1 suggests that men with ERG+ disease are more likely to carry the risk allele than men with ERG-disease, while an OR less than 1 suggests that men with ERG-disease more commonly carry the risk allele than men with ERG+ disease. Six SNPs were statistically significant comparing ERG+ to ERG-cancers (p<0.05), and another four SNPs were borderline statistically significant (p=0.06-0.07). By chance, in the ERG+ versus ERG-analysis, we would only expect two associations to be statistically significant at p<0.05 (i.e., 0.05 x 39 = 1.95). When we examined the patterns of the association for the ten SNPs differentially associated with ERG+ or ERG-we found four were significantly associated with ERG+ compared to controls but not ERG-(rs7679673, rs902774, rs11672691, rs1859962), three were significantly associated with ERG-compared to controls but not ERG+ (rs2660753, rs7629490, rs1016343), and the associations trending in opposite directions for ERG+ and ERG-for three (rs12653946, rs1512268, rs11704416).
Discussion
Our findings suggest that tumors that develop the TMPRSS2:ERG fusion, one of the most common alterations in prostate cancer, have a different genetic etiology from those that do not. We observed several known prostate cancer risk SNPs are differentially associated with the risk of developing prostate tumors either with or 
without the fusion. Such specificity has been observed in breast cancer subtypes, where GWAS have identified unique loci associated with the risk of ER-positive or ER-negative disease [27] .
TMPRSS2:ERG is thought to be an early event in carcinogenesis, and our data indicate that inherited genetic variation may influence its occurrence. We have previously shown that some of these SNPs function as cis acting expression Quantitative Trait Loci (eQTL), and were associated with the expression of KRT6B, SP7, AXL, DMRTC2, CHMP2B, and IRX4 in tumor [28] . These genes are now candidates for possible mechanisms for TMPRSS2:ERG fusion development. Our results also are in line with the study that suggested a familial susceptibility of developing fusion positive prostate cancer [29] -this linkage analysis suggested several loci located on chromosomes 9, 18, and X were associated with fusion-positive prostate cancer. Moreover, we recently reported that shorter CAG repeat length in the androgen receptor (AR) was associated with an increased risk of ERG+ but not ERG-disease [30]. Additionally, rare variants in the DNA repair genes POLI and ESCO1 were associated with an increased risk of ERG+ cancer [31] . Taken together, these data demonstrate the importance and usefulness of studying molecular subtypes individually. In attempting to discover new risk factors for prostate cancer, genetic or otherwise, this strategy should be considered.
Despite being underpowered given the known small effect sizes of these risk variants, we still observed several SNPs exclusively associated with the risk of fusion positive or fusion negative disease. However, we did not adjust for multiple comparisons, using only p<0.05 as significant [Bonferroni corrected significance would be p<0.0013 in the main ERG+ vs ERG-analysis], so these results could be due to chance. Validation of these results should be attempted in additional studies. These findings suggest that the molecular process of prostate carcinogenesis may be distinct for men with different underlying genetic predisposition. We hypothesize there may be additional genetic variants that uniquely contribute to the development of fusion positive or negative prostate cancer. Specifically identifying SNPs associated with fusion negative tumors may uncover genes and pathways that help define other molecular subtypes. When attempting to identify risk factors for prostate cancer, molecular subtypes of disease should be considered separately. 
